CTXR (Citius Pharmaceuticals Inc. Common) Stock Analysis - Hedge Fund Holdings

Citius Pharmaceuticals Inc. Common (CTXR) is a publicly traded Healthcare sector company. As of May 21, 2026, CTXR trades at $0.57 with a market cap of $14.47M and a P/E ratio of -0.26. CTXR moved +4.31% today. Year to date, CTXR is -38.29%; over the trailing twelve months it is -21.47%. Its 52-week range spans $0.48 to $13.52. Rallies surfaces CTXR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CTXR stock?

Hedge funds tracked by Rallies that own CTXR include Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Citius Pharmaceuticals Inc. Common.

CTXR Key Metrics

Key financial metrics for CTXR
MetricValue
Price$0.57
Market Cap$14.47M
P/E Ratio-0.26
EPS$-2.24
Dividend Yield0.00%
52-Week High$13.52
52-Week Low$0.48
Volume4.24K
Avg Volume0
Revenue (TTM)$5.61M
Net Income$-55.45M
Gross Margin0.00%

Top Hedge Funds Holding CTXR

  • Citadel Advisors holds 1 shares of CTXR, changed -100.00% as of Dec 31, 2024.

Latest CTXR News

CTXR Analyst Consensus

CTXR analyst coverage data. Average price target: $0.00.

Common questions about CTXR

Who owns CTXR stock?
Hedge funds tracked by Rallies that own CTXR include Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Citius Pharmaceuticals Inc. Common.
Does Rallies show 13F holders for CTXR?
Yes. Rallies tracks hedge fund and 13F ownership data for CTXR, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CTXR research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CTXR. It does not provide personalized investment advice.
CTXR

CTXR